Cassava Sciences Inc

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cassava Sciences advances Phase III trial with strong financial footing

Cassava Sciences is progressing well with Phase III trial milestones and financial stability, poised to announce critical trial results by year-end.
While facing challenges in data accuracy and increased expenses, the company's proactive approach and strategic planning present significant growth opportunities.
By focusing on innovation and market transformation, Cassava Sciences is positioned to redefine Alzheimer's disease diagnosis and treatment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

-  Study  Showed High Variability in Levels of CSF Biomarkers Over 28 Days  -

Top-line Results from a Phase 2b Study of PTI-125 in Alzheimer’s Disease Does Not Meet Primary Endpoint

Alexion Pharma

Avid Technology

B2Gold

CURO Group Hlds

If other factors are constant while comparing stocks, the one with a higher earnings yield has the potential to provide comparatively greater returns.

Add Value to Your Portfolio With 5 High Earnings Yield Picks

- Grant Will Support an On-going Clinical Evaluation of Lead Investigational Drug PTI-125 in Alzheimer’s Disease -

Cassava Sciences Announces New $2.5 Million Research Grant Award from National Institutes of Health

Approximately 100 Study Participants Will Receive PTI-125 For 12 Months Approximately 100 Study Participants Will Receive PTI-125 For 12 Months

Cassava Sciences Announces Initiation of an Open-Label Study to Evaluate PTI-125 in Patients with Alzheimer’s Disease

AUSTIN, Texas, March  19, 2020  (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced clinical updates and business progress across its pipeline of product candidates under development.

Cassava Sciences Announces Clinical Update and Business Progress Across Neuroscience Pipeline

During the Q4 investors' call, Cassava Sciences (SAVA) is likely to provide an update on its lead candidate PT-125, which is being developed for the treatment of Alzheimer's disease.

What Lies Ahead for Cassava Sciences (SAVA) in Q4 Earnings?

AUSTIN, Texas, Feb.  11, 2020  (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that The Journal of Prevention of Alzheimer’s Disease (JPAD), a peer-reviewed journal for the research community, published results from the Company’s Phase 2a study demonstrating that its lead drug candidate, PTI-125, reduced biomarkers of disease in Alzheimer’s patients.

Cassava Sciences Announces Phase 2a Study of PTI-125 Published in  The Journal of Prevention of Alzheimer’s Disease (JPAD)

Top-Line Results Expected Mid-year 2020 Top-Line Results Expected Mid-year 2020

Cassava Sciences Announces Completion of Patient Enrollment of a Phase 2b Study in Alzheimer’s Disease

Cassava Sciences: An Investment Opportunity With Some Volatile Periods But A Net Upside

Agile Therapeutics

Air Industries Group

Journey Medical Corp

Microbot Medical

Multibagger stocks can make most of the bull run, courtesy of strong fundamentals and businesses that can multiply in a short span of time.

Buy Multibagger Stocks as Odds of a Rally Are High in 2020

Cue Biopharma

EverBank Financial

Fulgent Genetics

Teekay Tankers

U.S. stocks rallied to attained fresh all-time highs in 2019, as the momentum continued in 2020. Here are five stocks that are poised to grow.

5 Stocks to Soar in 2020 After Solid Gains in 2019

Shares of Cassava Sciences Inc. SAVA, -15.03% , which is developing treatments for Alzheimer's disease, jumped 33% on heavy volume in premarket trading on Thursday.

Cassava's stock rises 33%

Shares of Cassava Sciences Inc. jumped 24% on positive data from a mid-stage trial for its experimental Alzheimer's disease drug, PTI-125.

Cassava stock is up on Alzheimer's data

- New Data Shows Clinical Evidence of Target Engagement and Target Validation –

Cassava Sciences Announces Additional Positive Phase 2a Clinical Data in Alzheimer’s Disease at CTAD 2019

- Phase 2a Study Showed Statistically Significant Decreases (p

Cassava Sciences Announces Recent Clinical Highlights and Third Quarter 2019 Financial Results

AUSTIN, Texas, Oct.  24, 2019  (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biopharmaceutical company focused on Alzheimer’s disease, today announced that clinical results of its Phase 2a study of PTI-125 have been selected as a late-breaking oral presentation by the 12th International Conference on Clinical Trials on Alzheimer’s Disease  (CTAD). CTAD is a prestigious annual conference focused on Alzheimer’s research and development and takes place this year in San Diego, CA, on December 4-7th, 2019.

Cassava Sciences’ Clinical Results in Alzheimer’s Selected as Late-Breaking News at CTAD 2019

News for Cassava Sciences Inc Stock (SAVA)